DISPENSAÇÃO DE DROGAS MODIFICADORAS DE DOENÇA PARA ESCLEROSE MÚLTIPLA NO BRASIL APÓS O PROTOCOLO CLÍNICO E DIRETRIZES TERAPÊUTICAS DE 2021: uma análise observacional em big data do Sistema Único de Saúde

Detalhes bibliográficos
Ano de defesa: 2026
Autor(a) principal: Alexandre Coelho Marques lattes
Orientador(a): Livia Almeida Dutra lattes
Banca de defesa: Não Informado pela instituição
Tipo de documento: Dissertação
Tipo de acesso: Acesso aberto
Idioma: por
Instituição de defesa: Faculdade Israelita de Ciências da Saúde Albert Einstein
Programa de Pós-Graduação: Acadêmico em Ciências da Saúde
Departamento: Não Informado pela instituição
País: Brasil
Palavras-chave em Português:
Palavras-chave em Inglês:
Link de acesso: https://repositorio.einstein.br/publicacao/172733
Resumo: Introduction: Multiple sclerosis is the most frequent disabling non-traumatic neurological disease in young adults of working age. New, more effective drugs, especially for patients with highly active disease, have been incorporated into the Clinical Protocol and Therapeutic Guidelines of the Brazilian Unified Health System updated in 2021. The use of these highly effective drugs, such as natalizumab and alemtuzumab, is associated with a better prognosis. Despite the high cost of multiple sclerosis treatment for the Brazilian Unified Health System, there are no national studies evaluating the impact of this update on the pattern of medication dispensing. Purpose: To compare the pattern of medication dispensing for multiple sclerosis before and after the 2021 update of the Clinical Protocol and Therapeutic Guidelines; to analyze regional inequalities in the dispensing of disease-modifying drugs; to evaluate the relationship between the distance traveled by patients from their municipality of residence to the dispensing center and the dispensing of highly effective therapies in the Brazilian Unified Health System, using big data tools. Methods: An observational study based on administrative data from authorizations for highly complex outpatient procedures in the Brazilian Unified Health System Outpatient Information System, covering the period from 2019 to 2023, including patients diagnosed with multiple sclerosis. The following variables were analyzed: National Health Card number, disease-modifying drug, municipality of residence, and municipality of the dispensing center. The pattern of medication dispensing was evaluated using time series and quasi-Poisson regression models, with a descriptive and comparative approach between the periods before and after the 2021 protocol update, at the national, regional, and state levels. The distance traveled between the municipality of residence and the dispensing center was estimated using a geographic routing tool. Statistical analysis included augmented Dickey-Fuller, Cox-Stuart, Fisher’s g, Kruskal-Wallis, and Spearman correlation tests. Analyses were performed using R software (p<0.05). Results: Between 2019 and 2023, the number of multiple sclerosis patients treated by the Brazilian Unified Health System increased by 25.91%, with 71.98% being women in 2023. After the 2021 protocol update, a heterogeneous change in the pattern of medication dispensing in Brazil was observed. There was an increase in the dispensing of natalizumab (+44.5%), fingolimod (+15.8%), teriflunomide (+32.5%), and dimethyl fumarate (+53.1%), concomitant with a reduction in beta-interferons (-40.3%) and glatiramer acetate (-27.6%) (all with p<0.001). Regionally, there was an increase in the dispensing of natalizumab in all regions, with the North (+82%; p=0.042) and Northeast (+52%; p=0.039) standing out. The reduction in beta-interferons was significant only in the North region (-41.9%; p=0.049). The greatest distance traveled by patients was observed in the Central-West region (median: 234.06km [129.99-375.36]). In the analysis by federative units, no association was observed between the distance traveled by patients and the proportion of natalizumab dispensing (?=0.157; p=0.434). In the Amazon Basin, the greatest distance traveled by patients was recorded in Amazonas (414.79 km [154.82–807.57]), with no association with the proportion of natalizumab dispensing (?=0.36; p=0.444). Conclusions: The 2021 protocol update had a heterogeneous impact on the dispensing of disease-modifying drugs in Brazil, highlighting persistent regional inequalities in access to multiple sclerosis treatment. The absence of an association between the distance traveled by patients and the dispensing of more effective therapies suggests that structural, organizational, and professional training factors exert a more relevant influence on access to these treatments than geographical distance.
id HAE-1_8f9e3386ef1bc8ee9fa5f3f63d2916cb
oai_identifier_str oai:repositorio.einstein.br:172733
network_acronym_str HAE-1
network_name_str Repositório Einstein de Produção Intelectual (REPI)
repository_id_str
spelling porDISPENSAÇÃO DE DROGAS MODIFICADORAS DE DOENÇA PARA ESCLEROSE MÚLTIPLA NO BRASIL APÓS O PROTOCOLO CLÍNICO E DIRETRIZES TERAPÊUTICAS DE 2021: uma análise observacional em big data do Sistema Único de SaúdeDispensing of disease-modifying therapies for multiple sclerosis in Brazil following the 2021 clinical protocol and therapeutic guidelines: a big data observational analysis of the Brazilian Unified Health SystemIntroduction: Multiple sclerosis is the most frequent disabling non-traumatic neurological disease in young adults of working age. New, more effective drugs, especially for patients with highly active disease, have been incorporated into the Clinical Protocol and Therapeutic Guidelines of the Brazilian Unified Health System updated in 2021. The use of these highly effective drugs, such as natalizumab and alemtuzumab, is associated with a better prognosis. Despite the high cost of multiple sclerosis treatment for the Brazilian Unified Health System, there are no national studies evaluating the impact of this update on the pattern of medication dispensing. Purpose: To compare the pattern of medication dispensing for multiple sclerosis before and after the 2021 update of the Clinical Protocol and Therapeutic Guidelines; to analyze regional inequalities in the dispensing of disease-modifying drugs; to evaluate the relationship between the distance traveled by patients from their municipality of residence to the dispensing center and the dispensing of highly effective therapies in the Brazilian Unified Health System, using big data tools. Methods: An observational study based on administrative data from authorizations for highly complex outpatient procedures in the Brazilian Unified Health System Outpatient Information System, covering the period from 2019 to 2023, including patients diagnosed with multiple sclerosis. The following variables were analyzed: National Health Card number, disease-modifying drug, municipality of residence, and municipality of the dispensing center. The pattern of medication dispensing was evaluated using time series and quasi-Poisson regression models, with a descriptive and comparative approach between the periods before and after the 2021 protocol update, at the national, regional, and state levels. The distance traveled between the municipality of residence and the dispensing center was estimated using a geographic routing tool. Statistical analysis included augmented Dickey-Fuller, Cox-Stuart, Fisher’s g, Kruskal-Wallis, and Spearman correlation tests. Analyses were performed using R software (p<0.05). Results: Between 2019 and 2023, the number of multiple sclerosis patients treated by the Brazilian Unified Health System increased by 25.91%, with 71.98% being women in 2023. After the 2021 protocol update, a heterogeneous change in the pattern of medication dispensing in Brazil was observed. There was an increase in the dispensing of natalizumab (+44.5%), fingolimod (+15.8%), teriflunomide (+32.5%), and dimethyl fumarate (+53.1%), concomitant with a reduction in beta-interferons (-40.3%) and glatiramer acetate (-27.6%) (all with p<0.001). Regionally, there was an increase in the dispensing of natalizumab in all regions, with the North (+82%; p=0.042) and Northeast (+52%; p=0.039) standing out. The reduction in beta-interferons was significant only in the North region (-41.9%; p=0.049). The greatest distance traveled by patients was observed in the Central-West region (median: 234.06km [129.99-375.36]). In the analysis by federative units, no association was observed between the distance traveled by patients and the proportion of natalizumab dispensing (?=0.157; p=0.434). In the Amazon Basin, the greatest distance traveled by patients was recorded in Amazonas (414.79 km [154.82–807.57]), with no association with the proportion of natalizumab dispensing (?=0.36; p=0.444). Conclusions: The 2021 protocol update had a heterogeneous impact on the dispensing of disease-modifying drugs in Brazil, highlighting persistent regional inequalities in access to multiple sclerosis treatment. The absence of an association between the distance traveled by patients and the dispensing of more effective therapies suggests that structural, organizational, and professional training factors exert a more relevant influence on access to these treatments than geographical distance.Introdução: A esclerose múltipla é a doença neurológica não traumática incapacitante mais frequente em adultos jovens, em idade economicamente ativa. Novas drogas de maior eficácia, especialmente para pacientes com doença altamente ativa, foram incorporadas ao Protocolo Clínico e Diretrizes Terapêuticas do Sistema Único de Saúde atualizado em 2021. O uso dessas drogas de alta eficácia, como natalizumabe e alentuzumabe, está associado a melhor prognóstico. Apesar do alto custo do tratamento da esclerose múltipla para o Sistema Único de Saúde, não há estudos nacionais que avaliem o impacto dessa atualização sobre o padrão de dispensação de medicamentos. Objetivos: Comparar o padrão de dispensação de medicamentos para esclerose múltipla antes e após a atualização do Protocolo Clínico e Diretrizes Terapêuticas de 2021; analisar desigualdades regionais na dispensação de drogas modificadoras de doença; e avaliar a relação entre a distância percorrida pelos pacientes do município de residência ao centro de dispensação e a dispensação de terapias de alta eficácia no Sistema Único de Saúde, utilizando ferramentas de big data. Métodos: Estudo observacional baseado em dados administrativos das autorizações de procedimentos ambulatoriais de alta complexidade do Sistema de Informação Ambulatorial do Sistema Único de Saúde, referente ao período de 2019 a 2023, incluindo pacientes com diagnóstico de esclerose múltipla. Foram analisadas as seguintes variáveis: número do Cartão Nacional de Saúde, droga modificadora de doença, município de residência e município do centro de dispensação. O padrão de dispensação de medicamentos foi avaliado por meio de séries temporais e modelos de regressão quasi-Poisson, com abordagem descritiva e comparativa entre os períodos pré e pós-atualização do protocolo de 2021, nos níveis nacional, regional e estadual. A distância percorrida entre o município de residência e o centro de dispensação foi estimada por ferramenta de roteamento geográfico. A análise estatística incluiu testes Dickey-Fuller aumentado, Cox-Stuart, Fisher’s g, Kruskal-Wallis e correlação de Spearman. As análises foram realizadas no software R (p<0,05). Resultados: Entre 2019 e 2023, o número de pacientes com esclerose múltipla atendidos pelo Sistema Único de Saúde aumentou 25,91%, sendo 71,98% mulheres em 2023. Após a atualização do protocolo de 2021, observou-se mudança heterogênea no padrão de dispensação de medicamentos no Brasil. Houve aumento na dispensação de natalizumabe (+44,5%), fingolimode (+15,8%), teriflunomida (+32,5%) e fumarato de dimetila (+53,1%), concomitante à redução de betainterferonas (-40,3%) e acetato de glatiramer (-27,6%) (todos com p<0,001). Regionalmente, houve aumento na dispensação de natalizumabe em todas as regiões, com destaque para o Norte (+82%; p=0,042) e Nordeste (+52%; p=0,039). A redução das betainterferonas foi significativa apenas na região Norte (-41,9%; p=0,049). A maior distância percorrida pelos pacientes foi observada na região Centro-Oeste (mediana: 234,06 km [129,99-375,36]). Na análise por unidades federativas, não se observou associação entre a distância percorrida pelos pacientes e a proporção de dispensação de natalizumabe (?=0,157; p=0,434). Na Bacia Amazônica, a maior distância percorrida pelos pacientes foi registrada no Amazonas (414,79 km [154,82–807,57]), sem associação com a proporção de dispensação de natalizumabe (?=0,36; p=0,444). Conclusões: A atualização do protocolo de 2021 impactou de forma heterogênea a dispensação de drogas modificadoras de doença no Brasil, evidenciando desigualdades regionais persistentes no acesso ao tratamento da esclerose múltipla. A ausência de associação entre a distância percorrida pelos pacientes e a dispensação de terapias de maior eficácia sugere que fatores estruturais, organizacionais e de capacitação profissional exerçam influência mais relevante no acesso a esses tratamentos do que a distância geográfica.Big dataEsclerose múltiplaProtocolos clínicosGuia de prática clínicaNatalizumabBig dataMultiple sclerosisClinical protocolsNatalizumabinfo:eu-repo/semantics/masterThesisinfo:eu-repo/semantics/publishedVersionLivia Almeida Dutrahttp://lattes.cnpq.br/2916631594056232http://lattes.cnpq.br/2955600971230359Alexandre Coelho MarquesFaculdade Israelita de Ciências da Saúde Albert EinsteinAcadêmico em Ciências da SaúdeBrasil2026https://repositorio.einstein.br/publicacao/172733oai:repositorio.einstein.br:172733reponame:Repositório Einstein de Produção Intelectual (REPI)instname:Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein (SBIBAE)instacron:SBIBAEinfo:eu-repo/semantics/openAccessRepositório InstitucionalPRIhttps://repositorio.einstein.br/oai || https://api.einstein.br/prd/plataformacientifica/sgpcri/api/oai2repositorioinstitucional@einstein.bropendoar:2026-02-27T00:00Repositório Einstein de Produção Intelectual (REPI) - Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein (SBIBAE)falseoai:repositorio.einstein.br:172733
dc.title.por.fl_str_mv DISPENSAÇÃO DE DROGAS MODIFICADORAS DE DOENÇA PARA ESCLEROSE MÚLTIPLA NO BRASIL APÓS O PROTOCOLO CLÍNICO E DIRETRIZES TERAPÊUTICAS DE 2021: uma análise observacional em big data do Sistema Único de Saúde
dc.title.alternative.eng.fl_str_mv Dispensing of disease-modifying therapies for multiple sclerosis in Brazil following the 2021 clinical protocol and therapeutic guidelines: a big data observational analysis of the Brazilian Unified Health System
title DISPENSAÇÃO DE DROGAS MODIFICADORAS DE DOENÇA PARA ESCLEROSE MÚLTIPLA NO BRASIL APÓS O PROTOCOLO CLÍNICO E DIRETRIZES TERAPÊUTICAS DE 2021: uma análise observacional em big data do Sistema Único de Saúde
spellingShingle DISPENSAÇÃO DE DROGAS MODIFICADORAS DE DOENÇA PARA ESCLEROSE MÚLTIPLA NO BRASIL APÓS O PROTOCOLO CLÍNICO E DIRETRIZES TERAPÊUTICAS DE 2021: uma análise observacional em big data do Sistema Único de Saúde
Alexandre Coelho Marques
Big data
Esclerose múltipla
Protocolos clínicos
Guia de prática clínica
Natalizumab
Big data
Multiple sclerosis
Clinical protocols
Natalizumab
title_short DISPENSAÇÃO DE DROGAS MODIFICADORAS DE DOENÇA PARA ESCLEROSE MÚLTIPLA NO BRASIL APÓS O PROTOCOLO CLÍNICO E DIRETRIZES TERAPÊUTICAS DE 2021: uma análise observacional em big data do Sistema Único de Saúde
title_full DISPENSAÇÃO DE DROGAS MODIFICADORAS DE DOENÇA PARA ESCLEROSE MÚLTIPLA NO BRASIL APÓS O PROTOCOLO CLÍNICO E DIRETRIZES TERAPÊUTICAS DE 2021: uma análise observacional em big data do Sistema Único de Saúde
title_fullStr DISPENSAÇÃO DE DROGAS MODIFICADORAS DE DOENÇA PARA ESCLEROSE MÚLTIPLA NO BRASIL APÓS O PROTOCOLO CLÍNICO E DIRETRIZES TERAPÊUTICAS DE 2021: uma análise observacional em big data do Sistema Único de Saúde
title_full_unstemmed DISPENSAÇÃO DE DROGAS MODIFICADORAS DE DOENÇA PARA ESCLEROSE MÚLTIPLA NO BRASIL APÓS O PROTOCOLO CLÍNICO E DIRETRIZES TERAPÊUTICAS DE 2021: uma análise observacional em big data do Sistema Único de Saúde
title_sort DISPENSAÇÃO DE DROGAS MODIFICADORAS DE DOENÇA PARA ESCLEROSE MÚLTIPLA NO BRASIL APÓS O PROTOCOLO CLÍNICO E DIRETRIZES TERAPÊUTICAS DE 2021: uma análise observacional em big data do Sistema Único de Saúde
author Alexandre Coelho Marques
author_facet Alexandre Coelho Marques
author_role author
dc.contributor.advisor1.fl_str_mv Livia Almeida Dutra
dc.contributor.advisor1Lattes.fl_str_mv http://lattes.cnpq.br/2916631594056232
dc.contributor.authorLattes.fl_str_mv http://lattes.cnpq.br/2955600971230359
dc.contributor.author.fl_str_mv Alexandre Coelho Marques
contributor_str_mv Livia Almeida Dutra
dc.subject.por.fl_str_mv Big data
Esclerose múltipla
Protocolos clínicos
Guia de prática clínica
Natalizumab
topic Big data
Esclerose múltipla
Protocolos clínicos
Guia de prática clínica
Natalizumab
Big data
Multiple sclerosis
Clinical protocols
Natalizumab
dc.subject.eng.fl_str_mv Big data
Multiple sclerosis
Clinical protocols
Natalizumab
description Introduction: Multiple sclerosis is the most frequent disabling non-traumatic neurological disease in young adults of working age. New, more effective drugs, especially for patients with highly active disease, have been incorporated into the Clinical Protocol and Therapeutic Guidelines of the Brazilian Unified Health System updated in 2021. The use of these highly effective drugs, such as natalizumab and alemtuzumab, is associated with a better prognosis. Despite the high cost of multiple sclerosis treatment for the Brazilian Unified Health System, there are no national studies evaluating the impact of this update on the pattern of medication dispensing. Purpose: To compare the pattern of medication dispensing for multiple sclerosis before and after the 2021 update of the Clinical Protocol and Therapeutic Guidelines; to analyze regional inequalities in the dispensing of disease-modifying drugs; to evaluate the relationship between the distance traveled by patients from their municipality of residence to the dispensing center and the dispensing of highly effective therapies in the Brazilian Unified Health System, using big data tools. Methods: An observational study based on administrative data from authorizations for highly complex outpatient procedures in the Brazilian Unified Health System Outpatient Information System, covering the period from 2019 to 2023, including patients diagnosed with multiple sclerosis. The following variables were analyzed: National Health Card number, disease-modifying drug, municipality of residence, and municipality of the dispensing center. The pattern of medication dispensing was evaluated using time series and quasi-Poisson regression models, with a descriptive and comparative approach between the periods before and after the 2021 protocol update, at the national, regional, and state levels. The distance traveled between the municipality of residence and the dispensing center was estimated using a geographic routing tool. Statistical analysis included augmented Dickey-Fuller, Cox-Stuart, Fisher’s g, Kruskal-Wallis, and Spearman correlation tests. Analyses were performed using R software (p<0.05). Results: Between 2019 and 2023, the number of multiple sclerosis patients treated by the Brazilian Unified Health System increased by 25.91%, with 71.98% being women in 2023. After the 2021 protocol update, a heterogeneous change in the pattern of medication dispensing in Brazil was observed. There was an increase in the dispensing of natalizumab (+44.5%), fingolimod (+15.8%), teriflunomide (+32.5%), and dimethyl fumarate (+53.1%), concomitant with a reduction in beta-interferons (-40.3%) and glatiramer acetate (-27.6%) (all with p<0.001). Regionally, there was an increase in the dispensing of natalizumab in all regions, with the North (+82%; p=0.042) and Northeast (+52%; p=0.039) standing out. The reduction in beta-interferons was significant only in the North region (-41.9%; p=0.049). The greatest distance traveled by patients was observed in the Central-West region (median: 234.06km [129.99-375.36]). In the analysis by federative units, no association was observed between the distance traveled by patients and the proportion of natalizumab dispensing (?=0.157; p=0.434). In the Amazon Basin, the greatest distance traveled by patients was recorded in Amazonas (414.79 km [154.82–807.57]), with no association with the proportion of natalizumab dispensing (?=0.36; p=0.444). Conclusions: The 2021 protocol update had a heterogeneous impact on the dispensing of disease-modifying drugs in Brazil, highlighting persistent regional inequalities in access to multiple sclerosis treatment. The absence of an association between the distance traveled by patients and the dispensing of more effective therapies suggests that structural, organizational, and professional training factors exert a more relevant influence on access to these treatments than geographical distance.
publishDate 2026
dc.date.issued.fl_str_mv 2026
dc.type.driver.fl_str_mv info:eu-repo/semantics/masterThesis
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format masterThesis
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://repositorio.einstein.br/publicacao/172733
oai:repositorio.einstein.br:172733
url https://repositorio.einstein.br/publicacao/172733
identifier_str_mv oai:repositorio.einstein.br:172733
dc.language.iso.fl_str_mv por
language por
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Faculdade Israelita de Ciências da Saúde Albert Einstein
dc.publisher.program.fl_str_mv Acadêmico em Ciências da Saúde
dc.publisher.country.fl_str_mv Brasil
publisher.none.fl_str_mv Faculdade Israelita de Ciências da Saúde Albert Einstein
dc.source.none.fl_str_mv reponame:Repositório Einstein de Produção Intelectual (REPI)
instname:Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein (SBIBAE)
instacron:SBIBAE
instname_str Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein (SBIBAE)
instacron_str SBIBAE
institution SBIBAE
reponame_str Repositório Einstein de Produção Intelectual (REPI)
collection Repositório Einstein de Produção Intelectual (REPI)
repository.name.fl_str_mv Repositório Einstein de Produção Intelectual (REPI) - Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein (SBIBAE)
repository.mail.fl_str_mv repositorioinstitucional@einstein.br
_version_ 1880933137595236352